Bernhardt G. Zeiher - 20 Mar 2025 Form 4 Insider Report for Amylyx Pharmaceuticals, Inc. (AMLX)

Reporting relationship: Director
Issuer ticker: AMLX
Reported as of: 20 Mar 2025
Net transaction value: +$37,005
SEC form: 4
Accepted by SEC: 24 Mar 2025, 16:15:37 UTC
Prior SEC filing: 03 Feb 2025
Next SEC filing: 09 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Joshua B. Cohen, as Attorney in Fact

Key filing fact

Bernhardt G. Zeiher filed Form 4 for Amylyx Pharmaceuticals, Inc. (AMLX) on 24 Mar 2025.

Key facts

This page summarizes Bernhardt G. Zeiher's Form 4 filing for Amylyx Pharmaceuticals, Inc. (AMLX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 24 Mar 2025, 16:15.

Change

Previous filing in this sequence was filed on 03 Feb 2025.
Current net transaction value: +$37,005.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AMLX transaction

Common Stock

Purchase

Transaction value: $37,005
Shares: +10,000
Change %
Price: $3.70
Shares after: 10,000
Date: 20 Mar 2025
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.65 to $3.73. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request.